Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial This study highlights that system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback